Hormone therapy and Alzheimer’s disease: benefit or harm?

Bibliography

• TREVOUX R, DE BRUX J,CASTANIER M, NAHOUL K,SOULE J-P, SCHOLLER R: Endometrium and plasma hormone profile in thepen-menopause and post-menopause. Maturitas (1986) 8:309–326.
   PubMed Web of Science ®Google Scholar
• MCKINLAY SM, BRAMBILLA DJ, POSNER JG: The normal menopause transition. Maturitas (1992) 14:103–115.
   PubMed Web of Science ®Google Scholar
• BURGER HG, DUDLEY EC,HOOPER JL et al.: Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimericinhibins during the menopausal transition in a population-based cohort of women. Clin. Endocrine]. Metab. (1999) 84:4025–4030.
   Google Scholar
• JUDD HL, FOURNET N: Changes of ovarian hormonal function with aging. Exp. Get-unto]. (1994) 29:285–298.
   PubMed Web of Science ®Google Scholar
• TONGS, WALLACE EM, BURGER HG: Inhibins and activins: clinical advances in reproductive medicine. Clin. Endocrinol(ux!) (2003) 58:115–127.
   PubMedGoogle Scholar
• BURGER HG, DUDLEY EC, CUT J,DENNERSTEIN L, HOPPER JL: A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition.Clin. Endocrinol Metal,. (2000) 85:2832–2838.
   PubMed Web of Science ®Google Scholar
• LAUNER LJ, ANDERSEN K,DEWEY ME et al.: Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. Neurology (1999) 52:78–84.
   Google Scholar
• KUKULL WA, HIGDON R, BOWEN JD et al.: Dementia and Alzheimer's disease incidence: a prospective cohort study. Arch. Neurol (2002) 59:1737–1746.
   PubMed Web of Science ®Google Scholar
• KNOPMAN DS, PARISI JE, BOEVE BF et al.: Vascular dementia in a population-based autopsy study. Arch. Neurol (2003) 60:569–575.
   PubMedGoogle Scholar
• JORM AF, KORTEN AE,HENDERSON AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. (1987) 76:465–479.
   PubMed Web of Science ®Google Scholar
• GAO S, HENDRIE HC, HALL KS, HUT S: The relationships between age, sex, and incidence of dementia and Alzheimer's disease: a meta-analysis. Arch. Gen. Psychiatry (1998) 55:809–815.
   PubMed Web of Science ®Google Scholar
• KEMPER TL: Neuroanatomical, and neuropathological changes during aging and dementia. In: Clinical Neurology of Aging (2'd edn). Albert ML, Knoefel JE (Eds), Oxford University Press, New York (1994):3–67.
   Google Scholar
• GOEDERT M, WISCHIK CM, CROWTHER RA, WALKER JE,KLUG A: Cloning and sequencing of the eDNA encoding a core protein of the paired helical filament of Alzheimer's disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. ScL USA (1988) 85:4051–4055.
   PubMed Web of Science ®Google Scholar
• GOATE A, CHARTIER-HARLIN M-C, MULLAN M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 349:704–706.
   PubMedGoogle Scholar
• SHERRINGTON R, ROGAEV ET, LIANG Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 375:754–760.
   PubMed Web of Science ®Google Scholar
• LEVY-LAHAD E, WIJSMAN EM, NEMENS E et al: A familial Alzheimer's disease locus on chromosome 1. Science (1995) 269:970–973.
   PubMed Web of Science ®Google Scholar
• HONG M, TROJANOWSKI JQ, LEE VM-Y: Tau-based neurofibrillary lesions. In: Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. Trojanowski JQ (Ed.), McGraw-Hill, New York (2000):161–175.
   Google Scholar
• GOTZ J, CHEN F, VAN DORPE J, NITSCH RM: Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A42 fibrils. Science (2001) 293:1491–1495.
   PubMed Web of Science ®Google Scholar
• POIRIER J: Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Ma Med. (2003) 9:94–101.
   PubMed Web of Science ®Google Scholar
• NASLUND J, THYBERG J,TJERNBERG LO et al.: Characterization of stable complexes involving apolipoprotein E and the amyloidl3 peptide in Alzheimer's disease brain. Neuron (1995) 15:219–228.
   Google Scholar
• GYLYS KH, FEIN JA, TAN AM, COLE GM: Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals.' Neurochem. (2003) 84:1442–1451.
   PubMedGoogle Scholar
• POLVIKOSKI T, SULKAVA R, HALTIA M et al: Apolipoprotein E, dementia, and cortical deposition of P-amyloid protein. N Engl.' Med. (1995) 333:1242–1247.
   PubMed Web of Science ®Google Scholar
• SELKOE DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 81:741–746.
   PubMed Web of Science ®Google Scholar
• •A review of genetic contributions to AD.
   Google Scholar
• FARRER LA, CUPPLES LA, HAINES JL et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease.JAMA (1997) 278:1349–1356.
   PubMed Web of Science ®Google Scholar
• BRETSKY PM, BUCKWALTERJG, SEEMAN TE et al.: Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer's disease. Alzheimer. Dis. Assoc. Disord. (1999) 13:216–221.
   PubMedGoogle Scholar
• STONE DJ, ROZOVSKY I, MORGAN TE, ANDERSON CP, HAJIAN H, FINCH CE: Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol (1997) 143:313–318.
   PubMedGoogle Scholar
• KATZMAN R: Education and the prevalence of dementia and Alzheimer's disease. Neurology(1993) 43:13–20.
   PubMed Web of Science ®Google Scholar
• MORTIMER JA, FRENCH LR, HUTTON JT, SCHUMAN LM: Head injury as a risk factor for Alzheimer's disease. Neurology (1985) 35:264–267.
   PubMed Web of Science ®Google Scholar
• SKOOG I, LERNFELT B, LANDAHL S et al.: 15-year longitudinal study of blood pressure and dementia. Lancet (1996) 347:1141–1145.
   PubMed Web of Science ®Google Scholar
• KIVIPELTO M, HELKALA EL, LAAKSO MP et al.: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. Br. Med. (2001) 322:1447–1451.
   PubMed Web of Science ®Google Scholar
• SESHADRI S, BEISER A, SELHUB J et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl.' Med. (2002) 346:476–483.
   PubMed Web of Science ®Google Scholar
• IN T' VELD BA, RUITENBERG A, HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl. I Med. (2001) 345:1515–1521.
   Google Scholar
• WOLOZIN B, KELLMAN W,RUOSSEAU P, CELESTA GG, SIEGEL G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.Arch. Neurol (2000) 57:1439–1443.
   PubMed Web of Science ®Google Scholar
• MUKAMAL KJ, KULLER LH, FITZPATRICK AL,LONGSTRETH WT Jr, MITTLEMAN MA, SISCOVICK DS: Prospective study of alcohol consumption and risk of dementia in older adults. JAMA (2003) 289:1405–1413.
   PubMed Web of Science ®Google Scholar
• WILSON RS, MENDES DE LEON CE BARNES LL et al.: Participation in cognitively stimulating activities and risk of incident Alzheimer's disease. JAMA (2002) 287:742–748.
   Google Scholar
• LAURIN D, VERREAULT R, LINDSAY J, MACPHERSON K, ROCKWOOD K: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch. Neurol (2001) 58:498–504.
   PubMed Web of Science ®Google Scholar
• SHUMAKER SA, LEGAULT C, RAPP SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS). JAMA (2003) 289:2651–2662.
   PubMed Web of Science ®Google Scholar
• ••The WHI randomised, controlled trial ofcontinuous combined oestrogen plus progestin in women aged 65–79 years, showing increased incidence for dementia but no incidence difference for mild cognitive impairment.
   Google Scholar
• GRONEMEYER H: Control oftranscription activation by steroid hormone receptors. FASEB (1992) 6:2524–2529.
   PubMed Web of Science ®Google Scholar
• SHUGHRUE PJ, LANE MV, MERCHENTHALER I: Comparative distribution of estrogen receptor-a and -13 mRNA in the rat central nervous system.Comp. Nemo]. (1997) 388:507–525.
   PubMed Web of Science ®Google Scholar
• SHUGHRUE PJ, SCRIMO PJ, MERCHENTHALER I: Evidence for the colocalization of estrogen receptor-beta mRNA and estrogen receptor-alpha immunoreactivity in neurons of the rat forebrain. Endocrinology (1998) 139:5267–5270.
   PubMedGoogle Scholar
• SHUGHRUE PJ, MERCHENTHALER I: Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system.' Comp. Neurol (2001) 436:64–81.
   PubMed Web of Science ®Google Scholar
• KUIPER GGJM, CARLSSON B, GRANDIEN K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and P. Endocrinology (1997) 138:863–870.
   PubMed Web of Science ®Google Scholar
• FALKENSTEIN E, NORMAN AW, WEHLING M: Mannheim classification of nongenomically initiated (rapid) steroid action(s).J. Clin. Endocrinol Metal,. (2000) 85:2072–2075.
   PubMed Web of Science ®Google Scholar
• WONG M, THOMPSON TL, MOSS RL: Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Crit. Rev Neurobiol. (1996) 10:189–203.
   PubMedGoogle Scholar
• LEVIN ER: Cellular functions of the plasma membrane estrogen receptor. Trends Endocrinol Metal,. (1999) 10:374–377.
   PubMed Web of Science ®Google Scholar
• MOOSMANN B, BEHL C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl. Acad. Sci. USA (1999) 96:8867–8872.
   PubMed Web of Science ®Google Scholar
• DYKENS JA, SIMPKINS JW, WANG J,GORDON K: Polycyclic phenols, estrogens and neuroprotection: a proposed mitochondrial mechanism. Exp. Cerontol (2003) 38:101–107.
   PubMedGoogle Scholar
• SANTAGATI S, MELCANGI RC, CELOTTI F, MARTINI L, MAGGI A: Estrogen receptor is expressed in different types of glial cells in culture. Neurochem. (1994) 63:2058–2064.
   PubMedGoogle Scholar
• SHI J, SIMPKINS JW: 1713-estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am. .1. Physiol (1997) 272:E1016–E1022.
   Google Scholar
• NAMBA H, SOKOLOFF L: Acute administration of high doses of estrogen increases glucose utilization throughout brain. Brain Res. (1984) 291:391–394.
   PubMedGoogle Scholar
• OHKURA T, TESHIMA Y, ISSE K et al: Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause (1995) 2:13–18.
   Web of Science ®Google Scholar
• COYLE JT, PRICE DL, DELONG MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science (1983) 219:1184–1190.
   PubMed Web of Science ®Google Scholar
• RASOOL CG, SVENDSEN CN, SELKOE DJ: Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease. Ann. Nemo]. (1986) 20:482–488.
   PubMedGoogle Scholar
• BONDAREFF W, MOUNTJOY CQ, ROTH M et al.: Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. (1987) 1:256–262.
   PubMedGoogle Scholar
• YAMAMOTO T, HIRANO A: Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons. Ann. Nemo]. (1985) 17:573–577.
   PubMedGoogle Scholar
• SHUGHRUE PJ, SCRIMO PJ,MERCHENTHALER I: Estrogen binding and estrogen receptor characterization (ERa and ERN in the cholinergic neurons of the rat basal forebrain. Neuroscience (2000) 96:41–49.
   PubMed Web of Science ®Google Scholar
• LUINE V: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol (1985) 89:484–490.
   PubMed Web of Science ®Google Scholar
• GABOR R, NAGLE R, JOHNSON DA, GIBBS RB: Estrogen enhances potassium-stimulated acetylcholine release in the rat hippocampus. Brain Res. (2003) 962:244–247.
   PubMedGoogle Scholar
• WU X, GLINN MA, OSTROWSKI NL et al.: Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. (1999) 847:98–104.
   PubMed Web of Science ®Google Scholar
• BETHEA CL, LU NZ, GUNDLAH C, STREICHER JM: Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol (2002) 23:41–100.
   PubMed Web of Science ®Google Scholar
• HERBISON AE, SIMONIAN SX, THANKY NR, BICKNELL RJ: Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. (2000) 230:74–85.
   PubMedGoogle Scholar
• HENDERSON VW: Hormone Therapy and the Brain: A Clinical Perspective on the Role of Estrogen. Parthenon Publishing, New York (2000).
   Google Scholar
• •An overview of the effects of HT on AD and other neurological and psychiatric disorders.
   Google Scholar
• SMITH MA, PERRY G, RICHEY PL et al.: Oxidative damage in Alzheimer's. Nature (1996) 382:120–121.
   PubMed Web of Science ®Google Scholar
• GOODMAN Y, BRUCE AJ, CHENG B, MATTSON MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid 13-peptide toxicity in hippocampal neurons.Neurochem. (1996) 66:1836–1844.
   PubMed Web of Science ®Google Scholar
• BEHL C, SKUTELLA T, LEZOUALCH F et al.: Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Ma Pharmacol. (1997) 51:535–541.
   PubMed Web of Science ®Google Scholar
• WANG J, GREEN PS, SIMPKINS JW: Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells.aNeurochem. (2001) 77:804–811.
   PubMed Web of Science ®Google Scholar
• REGAN RF, GUO Y: Estrogens attenuate neuronal injury due to hemoglobin, chemical hypwda, and excitatory amino acids in murine cortical cultures. Brant Res. (1997) 764:133–140.
   PubMedGoogle Scholar
• GARCIA-SEGURA LM, CARDONA-GOMEZ P, NAFTOLIN F, CHOWEN JA: Estradiol upregulates Bc1-2 expression in adult brain neurons. Neuroreport (1998) 9:593–597.
   PubMedGoogle Scholar
• PIKE CJ: Estrogen modulates neuronal Bc1-xL expression and 13-amyloid-induced apoptosis: relevance to Alzheimer's disease. Neurochem. (1999) 72:1552–1563.
   PubMedGoogle Scholar
• TORAN-ALLERAND CD,MIRANDA RC, BENTHAM WDL et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Nati Acad. Sci. USA (1992) 89:4668–4672.
   Google Scholar
• SOHRABJI F, MIRANDA RCG, TORAN-ALLERAND CD: Identification of a putative estrogen response element inthe gene encoding brain-derived neurotrophic factor. Proc. Natl.Acad. Sci. USA (1995) 92:11110–11114.
   PubMed Web of Science ®Google Scholar
• TORAN-ALLERAND CD: Organotypic culture of the developing cerebral cortex and hypothalamus: relevance to sexual differentiation. Psychoneuroendocrinology (1991) 16:7–24.
   PubMed Web of Science ®Google Scholar
• BRINTON RD, TRAN J, PROFFITT P,MONTOYA M: 17 I3-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem. Res. (1997) 22:1339–1351.
   PubMed Web of Science ®Google Scholar
• WOOLLEY CS, MCEWEN BS: Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J. Comp. Neurol (1993) 336:293–306.
   PubMed Web of Science ®Google Scholar
• SCHEIBEL ME, LINDSAY RD, TOMIYASU U, SCHEIBEL AN: Progressive dendritic changes in aging human cortex. Exp. Neurol (1975) 47:392–403.
   PubMed Web of Science ®Google Scholar
• MASLIAH E, MALLORY M, ALFORD M et al.: Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 56:127–129.
   PubMed Web of Science ®Google Scholar
• ESTUS S, TUCKER HM,VAN ROOYEN C et al: Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant `apoptotic' pattern of gene induction.Neurosci. (1997) 17:7736–7745.
   Google Scholar
• ROGERS J, COOPER NR, WEBSTER S et al.: Complement activation by beta-amyloid in Alzheimer's disease. Proc. Nati Acad. Sci. USA (1992) 89:10016–10020.
   PubMed Web of Science ®Google Scholar
• SMALL DH, NURCOMBE V, REED G et al.: A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. (1994) 14:2117–2127.
   PubMedGoogle Scholar
• MORIMOTO T, OHSAWA I, TAKAMURA C, ISHIGURO M, KOHSAKA S: Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons. Neurosci. Res. (1998) 51:185–195.
   Google Scholar
• LORENZO A, YANKNER BA: Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Nati Acad. Sci. USA (1994) 91:12243–12247.
   PubMed Web of Science ®Google Scholar
• BEHL C, LEZOUALC'H F, TRAPP T, WIDMANN M, SKUTELLA T, HOLSBOER F: Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology(1997) 138:101–106.
   PubMedGoogle Scholar
• HONJO H, KIKUCHI N, HOSODA T et al.: Alzheimer's disease and estrogen. J. Steroid Biochem. Ma Biol. (2001) 76:227–230.
   PubMedGoogle Scholar
• MARIN R, GUERRA B, MORALES A, DIAZ M, ALONSO R: An oestrogen membrane receptor participates in estradiol actions for the prevention of amyloid-I3 peptidei 4o-induced toxicity in septal-derived cholinergic 5N56 cells.aNeurochem. (2003) 85:1180–1189.
   PubMedGoogle Scholar
• SAGARA Y, DARGUSCH R, KLIER FG, SCHUBERT D, BEHL C: Increased antioxidant enzyme activity in amyloid protein-resistant cells. Neurosci. (1996) 16:497–505.
   Google Scholar
• JAFFE AB, TORAN-ALLERAND CD, GREENGARD P, GANDY SE: Estrogen regulates metabolism of Alzheimer amyloid 13 precursor protein. J. Biol. Chem. (1994) 269:13065–13068.
   PubMed Web of Science ®Google Scholar
• SEUBERT P, VIGO-PELFREY C, ESCH F et al: Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 359:268–269.
   PubMedGoogle Scholar
• XU H, GOURAS GK, GREENFIELD JP et al.: Estrogen reduces neuronal generation of Alzheimer 3-amyloid peptides. Nat. Med. (1998) 4:447–451.
   PubMed Web of Science ®Google Scholar
• ZHENG H, XU H, ULJON SN et al.: Modulation of Ap peptides by estrogen in mouse models. Neurochem. (2002) 80:191–196.
   PubMedGoogle Scholar
• PETANCESKA SS, NAGY G, FRAIL D, GANDY S: Ovariectomy and 1 713-estradiol modulate the levels of Alzheimer's amyloid 13 peptides in brain. Neurology(2000) 54:2212–2217.
   PubMed Web of Science ®Google Scholar
• •Ovariectomy increased levels of 3-amyloid in guinea-pig brain; oestradiol attenuated elevations in 3-amyloid.
   Google Scholar
• GREENFIELD JP, LEUNG LW, CAI D et al.: Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis. J. Biol. Chem. (2002) 277:12128–12136.
   Google Scholar
• KOJRO E, GIMPL G, LAMMICH S, MARZ W, FAHRENHOLZ F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect onthe a-secretase ADAM 10. Proc. Nati Acad. Sci. USA (2001) 98:5815–5820.
   PubMed Web of Science ®Google Scholar
• REFOLO LM, PAPPOLLA MA, LAFRANCOIS J et al: A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. (2001) 8:890–899.
   PubMed Web of Science ®Google Scholar
• WRITING GROUP FOR THE PEPI TRIAL: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA (1995) 273:199–208.
   PubMed Web of Science ®Google Scholar
• SCHLEGEL W, PETERSDORF LI, JUNKER R, SCHULTE H, EBERT C, VON ECKARDSTEIN A: The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. Clin. Endocrinol. (Ox!) (1999) 51:643–651.
   PubMed Web of Science ®Google Scholar
• LOBO RA, BUSH T, CARR BR, PICKARJH: Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Feral. Sterd. (2001) 76:13–24.
   PubMed Web of Science ®Google Scholar
• NEUROINFLAMMATION WORKING GROUP: Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 21:383–421.
   PubMed Web of Science ®Google Scholar
• SHEN Y, SULLIVAN T, LEE CM, MERI S, SHIOSAKI K, LIN CW: Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide. Brain Res. (1998) 796:187–197.
   PubMedGoogle Scholar
• TCHELINGERIAN JL, VIGNAIS L, JACQUE C: TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport (1994) 5:585–588.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, TANAKA K, NAGATA E, ITO D, DEMBO T, FUKUUCHI Y: Cerebral neurons express interleukin-6 after transient forebrain ischemia in gerbils. Neurosci. Lett. (1999) 262:117–120.
   PubMedGoogle Scholar
• GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to inflammation. N Engl. J. Med. (1999) 340:448–454.
   PubMed Web of Science ®Google Scholar
• PRADHAN AD, MANSON JE, ROSSOUW JE et al.: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women'sHealth Initiative observational study. JA/VIA (2002) 288:980–987.
   Google Scholar
• ROST NS, WOLF PA, KASE CS et al: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke (2001) 32:2575–2579.
   PubMed Web of Science ®Google Scholar
• CAO JJ, THACH C, MANOLIO TA et al: C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation (2003) 108:166–170.
   PubMed Web of Science ®Google Scholar
• WASSERTHEIL-SMOLLER S,HENDRIX S, LIMACHER M et al: Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JA/VIA (2003) 289:2673–2684.
   Google Scholar
• SCHMIDT R, SCHMIDT H, CURB JD, MASAKI K, WHITE LR, LAUNER LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol (2002) 52:168–174.
   PubMed Web of Science ®Google Scholar
• YASOJIMA K, SCHWAB C,MCGEER EG, MCGEER PL: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. (2000) 887:80–89.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, SCHULZER M, MCGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47:425–432.
   PubMed Web of Science ®Google Scholar
• LIM GP, YANG F, CHU T et al: Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Neurosci. (2000) 20:5709–5714.
   PubMed Web of Science ®Google Scholar
• GROSSMAN CJ: Interactions between the gonadal steroids and the immune system. Science (1985) 227:257–261.
   PubMed Web of Science ®Google Scholar
• THOMAS T, BRYANT M, CLARK L, GARCES A, RHODIN J: Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction.Microvasc. Res. (2001) 61:28–39.
   PubMed Web of Science ®Google Scholar
• CANTATORE FP, LOVERRO G, INGROSSO AM et al.: Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin. Rheumatol (1995) 14:157–160.
   PubMed Web of Science ®Google Scholar
• LUYER MD, KHOSLA S, OWEN WG, MILLER VM: Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation inapostmenopausal women. J. Clin. Endocrinol Metab. (2001) 86:3629–3634.
   PubMed Web of Science ®Google Scholar
• BERG G, EKERFELT C, HAMMAR M, LINDGREN R, MATTHIESEN L, ERNERUDH J: Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am. J. Reprod. Immunol (2002) 48:63–69.
   PubMed Web of Science ®Google Scholar
• BROOKS-ASPLUND EM, TUPPER CE, DAUN JM, KENNEY WL,aCANNON JG: Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women.Cytokine (2002) 19:193–200.
   PubMed Web of Science ®Google Scholar
• VONGPATANASIN W, TUNCEL M, WANG Z, ARBIQUE D, MEHRAD B, JIALAL I: Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J. Am. Coll. Cardiol (2003) 41:1358–1363.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, HENNEKENS CH, RIFAI N, BURING JE, MANSON JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation (1999) 100:713–716.
   PubMed Web of Science ®Google Scholar
• DECENSI A, OMODEI U, ROBERTSON C et al.: Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.Circulation (2002) 102:1224–1228.
   Google Scholar
• MODENA MG, BURSI F, FANTINI G et al.: Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. Am. j Med. (2002) 113:331–334.
   PubMed Web of Science ®Google Scholar
• POST MS, VAN DER MOOREN MJ, STEHOUWER CD et al.: Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb. Haemost. (2002) 88:605–610.
   Google Scholar
• VEGETO E, BELCREDITO S, ETTERI S et al.: Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl. Acad. Sci. USA (2003) 100:9614–9619.
   PubMed Web of Science ®Google Scholar
• BARD F, CANNON C, BARBOUR R et al.: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reducepathology in a mouse model of Alzheimer's disease. Nat. Med. (2000) 6:916–919.
   PubMed Web of Science ®Google Scholar
• WYSS-CORAY T, LOIKE JD, BRIONNE TC et al.: Adult mouse astrocytes degrade amyloid-I3 in vitro and in situ. Nat. Med. (2003) 9:453–457.
   PubMed Web of Science ®Google Scholar
• SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-I3 attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature (1999) 400:173–177.
   PubMed Web of Science ®Google Scholar
• NICOLL JA, WILKINSON D,HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-beta peptide: a case report.Nat. Med. (2003) 9:448–452.
   PubMed Web of Science ®Google Scholar
• AISEN PS, DAVIS KL, BERG JD et al: A randomized controlled trial of prednisone in Alzheimer's disease. Neurology (2000) 54:588–593.
   PubMed Web of Science ®Google Scholar
• AISEN PS, SCHAFER KA,GRUNDMAN M et al: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA (2003) 289:2819–2826.
   PubMed Web of Science ®Google Scholar
• SNOWDON DA, GREINER LH, MORTIMER JA, RILEY KP, GREINER PA, MARKESBERY WR: Brain infarction and the clinical expression of Alzheimer's disease. JA/VIA (1997) 277:813–817.
   Google Scholar
• VERMEER SE, PRINS ND, DEN HELIER T, HOFMAN A, KOUDSTAAL P, BRETELER MM: Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. (2003) 348:1215–1222.
   PubMed Web of Science ®Google Scholar
• HULETTE C, NOCHLIN D, MCKEEL D et al.: Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology (1997) 48:668–672.
   PubMedGoogle Scholar
• ZEKRY D, HAUW JJ, GOLD G: Mixed dementia: epidemiology, diagnosis, and treatment. Am. Ceriatr. Soc. (2002) 50:1431–1438.
   PubMed Web of Science ®Google Scholar
• JELLINGER KA, ATTEMS J: Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study.Acta Neuropathol (Ben) (2002) 105:14–17.
   PubMedGoogle Scholar
• ZEKRY D, DUYCKAERTS C, MOULIAS R et al.: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol (Berl) (2002) 103:481–487.
   PubMedGoogle Scholar
• OTT A, SLOOTER AJC, HOFMAN A et al.: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study. Lancet (1998) 351:1840–1843.
   PubMedGoogle Scholar
• OTT A, STOLK RP, VAN HARSKAMP F, POLS HA, HOFMAN A,BRETELER MM: Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology (1999) 53:1937–1942.
   PubMed Web of Science ®Google Scholar
• MACKNIGHT C, ROCKWOOD K, AWALT E, MCDOWELL I:Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dementia (2002) 14:77–83.
   Google Scholar
• TAN ZS, SESHADRI S, BEISER A et al: Plasma total cholesterol level as a risk factor for Alzheimer's disease: the Framingham Study. Arch. Intern. Med. (2003) 163:1053–1057.
   PubMed Web of Science ®Google Scholar
• NIWA K, KAZAMA K, YOUNKIN L, YOUNKIN SG, CARLSON GA, IADECOLA C: Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am.' Physiol. (2002) 283:H315–H323.
   Google Scholar
• OHKURA T, MATSUDA H, IWASAKI N et al: Effect of estrogen on regional cerebral blood flow in postmenopausal women. .1 fpn Menopause Soc. (1996) 4:254–261.
   Google Scholar
• GREENE RA: Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment ofAlzheimer's disease. hat.WomensMed. (2000) 45:253–257.
   Google Scholar
• RESNICK SM, MAKI PM, GOLSKI S, KRAUT MA, ZONDERMAN AB: Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm. Behav. (1998) 34:171–182.
   PubMed Web of Science ®Google Scholar
• MAKI PM, RESNICK SM: Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol. Aging (2000) 21:373–383.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN EH, GERHARD MD, UEHATA A et al: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. (1994) 121:936–941.
   PubMed Web of Science ®Google Scholar
• KOH KK, JIN DK, YANG SH et al: Vascular effects of synthetic or natural progestagen combined with conjugatedaequine estrogen in healthy postmenopausal women. Circulation (2001) 103:1961–1966.
   PubMed Web of Science ®Google Scholar
• GUETTA V, QUYYUMI AA, PRASAD A, PANZA JA, WACLAWIW M,CANNON III RO: The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation (1997) 96:2795–2801.
   PubMed Web of Science ®Google Scholar
• CHEN Z, YUHANNA IS,GALCHEVA-GARGOVA Z, KARAS RH, MENDELSOHN ME, SHAUL PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Clin. Invest. (1999) 103:401–406.
   Google Scholar
• HERRINGTON DM, ESPELAND MA, CROUSE JRR et al.: Estrogen replacement and brachial artery flow-mediated vasodilation in older women.Arterioscier. a/MA V3SC. Biol. (2001) 21:1955–1961.
   Google Scholar
• KHETAWAT G, FARADAY N,NEALEN ML et al: Humanmegakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood (2000) 95:2289–2296.
   PubMed Web of Science ®Google Scholar
• MOR G, SAPI E, ABRAHAMS VM et al: Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes.J. Immunol. (2003) 170:114–122.
   PubMed Web of Science ®Google Scholar
• MOLERO L, GARCIA-DURAN M, DIAZ-RECASENS J, RICO L, CASADO S, LOPEZ-FARRE A: Expression of estrogen receptor subtypes and neuronal nitric oxide synthase in neutrophils from women and men: regulation by estrogen. Cardiovasc. Res. (2002) 56:43–51.
   PubMedGoogle Scholar
• DE VALK-DE ROO GW,STEHOUWER CD, MEIJER P et al: Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. (1999) 19:2993–3000.
   PubMedGoogle Scholar
• NOZAKI M, OGATA R, KOERA K, HASHIMOTO K, NAKANO H: Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric (1999) 2:124–130.
   PubMedGoogle Scholar
• ACS N, VAJO Z, MIKLOS Z et al.: The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies. Cynecol. Endocrinol. (2002) 16:335–346.
   PubMed Web of Science ®Google Scholar
• LOWE GD, UPTON MN, RUMLEY A, MCCONNACHIE A, O'REILLY DS, WATT GC: Different effects of oral and transdermal hormone replacement therapies on Factor IX, APC resistance, t-PA, PAT and C-reactive protein: a cross-sectional population survey. Thromb. Haemost. (2002) 86:550–556.
   Google Scholar
• NORRIS LA, JOYCE M, O'KEEFFE N, SHEPPARD BL, BONNARJ: Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas (2002) 43:125–133.
   PubMed Web of Science ®Google Scholar
• ZEGURA B, KEBER I, SEBESTJEN M, KOENIG W: Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis (2003) 168:123–129.
   PubMed Web of Science ®Google Scholar
• ROSS R: Mechanisms of disease: atherosclerosis - an inflammatory disease. N. Engl.' Med. (1999) 340:115–126.
   PubMed Web of Science ®Google Scholar
• CHAN SY, MANCINI GB,KURAMOTO L, SCHULZER M, FROHLICH J, IGNASZEWSKI A: The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease.Am. CoIl. Cardiol. (2003) 42:1037–1043.
   PubMed Web of Science ®Google Scholar
• WALSH BW, SCHIFF I, ROSNER B, GREENBERG L, RAVNIKAR V, SACKS FM: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Eng]. Med. (1991) 325:1196–1204.
   PubMed Web of Science ®Google Scholar
• WATANABE T, AKISHITA M,NAKAOKA T et al: Estrogen receptor beta mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation. Cardiovasc. Res. (2003) 59:734–744.
   PubMed Web of Science ®Google Scholar
• SHAUL PW: Regulation of endothelial nitric oxide synthase: location, location, location. Ann. Rev Physiol. (2002) 64:749–774.
   PubMed Web of Science ®Google Scholar
• HODIS HN, MACK WJ, LOBO RA et al: Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2001) 135:939–953.
   PubMed Web of Science ®Google Scholar
• HERRINGTON DM, REBOUSSIN DM, BROSNIHAN KB et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Eng]. Med. (2000) 343:522–529.
   PubMed Web of Science ®Google Scholar
• ANGERER P, STORK S, KOTHNY W, SCHMITT P, VON SCHACKY C: Effect of oral postmenopausal hormonereplacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler. Thromb. Vase. Biol. (2001) 21:262–268.
   PubMed Web of Science ®Google Scholar
• HODIS HN, MACK WJ, AZEN SP et al: Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl.' Med. (2003) 349:535–545.
   PubMed Web of Science ®Google Scholar
• MANS ON JE, HSIA J, JOHNSON KC et al: Estrogen plus progestin and the risk of coronary heart disease. N Engl. I Med. (2003) 349:523–534.
   PubMedGoogle Scholar
• HULLEY S, GRADY D, BUSH T et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JA/VIA (1998) 280:605–613.
   Google Scholar
• GRODSTEIN F, MANS ON JE,STAMPFER MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann. Intern. Med. (2001) 135:1–8.
   PubMed Web of Science ®Google Scholar
• SIMON JA, HSIA J, CAULEY JA et al: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS).Circulation (2001) 103:638–642.
   PubMed Web of Science ®Google Scholar
• VISCOLI CM, BRASS LM,KERNAN WN, SARREL SM, SUISSA S, HORWITZ RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. Med. (2001) 345:1243–1249.
   PubMed Web of Science ®Google Scholar
• GRODSTEIN F, MANS ON JE, COLDITZ GA, WILLETT WC, SPEIZER FE, STAMPFER MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. (2000) 133:933–941.
   PubMed Web of Science ®Google Scholar
• HONJO H, OGINO Y, TANAKA K et al: An effect of conjugated estrogen to cognitive impairment in women with senile dementia - Alzheimer's type: a placebo-controlled double blind study. I. fpn Menopause Soc. (1993) 1:167–171.
   Google Scholar
• ASTHANA S, CRAFT S, BAKER LD et al.: Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology (1999) 24:657–677.
   PubMed Web of Science ®Google Scholar
• ASTHANA S, BAKER LD, CRAFT S et al.: High-dose estradiol improvescognition for women with AD: results of a randomized study. Neurology(2001) 57:605–612.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial.Neurology (2000) 54:295–301.
   PubMed Web of Science ®Google Scholar
• MULNARD RA, COTMAN CW, KAWAS C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA (2000) 283:1007–1015.
   PubMed Web of Science ®Google Scholar
• ••A randomised, controlled trial ofunopposed oral oestrogen in women with AD, showing no treatment effect on disease severity or progression.
   Google Scholar
• WANG PN, LIAO SQ, LIU RS et al: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 54:2061–2066.
   PubMed Web of Science ®Google Scholar
• THAL LJ, THOMAS RG, MULNARD R, SANO M, GRUNDMAN M, SCHNEIDER L: Estrogen levels do not correlate with improvement in cognition. Arch. Neurol. (2003) 60:209–212.
   PubMedGoogle Scholar
• DORAISWAMY PM, BIEBER F, KAISER L, KRISHNAN KR, REUNING-SCHERER J, GULANSKI B: The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology (1997) 48:1511–1517.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, WATT L, BUCKWALTER JG: Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology (1996) 21:421–430.
   PubMed Web of Science ®Google Scholar
• STURGEON SR, SCHAIRER C, BRINTON LA, PEARSON T, HOOVER RN: Evidence of a healthy estrogen user survivor effect. Epidemiology (1995) 6:227–231.
   PubMed Web of Science ®Google Scholar
• MATTHEWS KA, KULLER LH, WING RR, MEILAHN EN, PLANTINGA P: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am. Epidemiol. (1996) 143:971–978.
   Google Scholar
• BARTUS RT, DEAN RL, BEER B, LIPPA AD: The cholinergic hypothesis of geriatric memory dysfunction. Science (1981) 217:208–217.
   Google Scholar
• CONNER JM, CULBERSON A, PACKOWSKI C, CHIBA AA, TUSZYNSKI MH: Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron (2003) 38:819–829.
   PubMed Web of Science ®Google Scholar
• SINGH M, MEYER EM, MILLARD WJ, SIMPKINS JW: Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. (1994) 644:305–312.
   PubMed Web of Science ®Google Scholar
• FADER AJ, HENDRICSON AW, DOHANICH GP: Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally. Neurobiol. Learn. Mem. (1998) 69:225–240.
   PubMed Web of Science ®Google Scholar
• GIBBS RB: Basal forebrain cholinergic neurons are necessary for estrogen to enhance acquisition of a delayed matching-to-position T-maze task. Horm. Behav. (2002) 42:245–257.
   PubMedGoogle Scholar
• DAVIS KL, THAL LJ, GAMZU ER et al.: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl.' Med. (1992) 327:1253–1259.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FARLOW MR,DOODY RS, MOHS R, FRIEDHOFF LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br. Med. J. (1999) 318:633–640.
   PubMed Web of Science ®Google Scholar
• RASKIND MA, PESKIND ER, WESSEL T, YUAN W: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology (2000) 54:2261–2268.
   Google Scholar
• SCHNEIDER LS, FARLOW MR, HENDERSON VW, POGODA JM: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology (1996) 46:1580–1584.
   PubMed Web of Science ®Google Scholar
• RIGAUD AS, ANDRE G, VELLAS B, TOUCHON J, PERE JJ: No additional benefit of HRT on response to rivastigminein menopausal women with AD. Neurology (2003) 60:148–149.
   PubMed Web of Science ®Google Scholar
• MANLY JJ, MERCHANT CA,JACOBS DM et al.: Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology (2000) 54:833–837.
   Google Scholar
• HOGERVORST E, SMITH AD: The interaction of serum folate and estradiol levels in Alzheimer's disease. Neuroendocrinol Lett. (2002) 23:155–160.
   PubMedGoogle Scholar
• GEERLINGS MI, LAUNER LJ,DE JONG FH et al.: Endogenous estradiol and risk of dementia in women and men: the Rotterdam Study. Ann. Neurol (2003) 53:607–615.
   Google Scholar
• HEYMAN A, WILKINSON WE, STAFFORD JA, HELMS JJ, SIGMON AH, WEINBERG T: Alzheimer's disease: a study of epidemiological aspects. Ann. Nemo] (1984) 15:335-341.Hs. AMADUCCI LA, FRATIGLIONI L, ROCCA WA et al.: Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology (1986) 36:922–931.
   Google Scholar
• BROE GA, HENDERSON AS, CREASEY H et al.: A case-control study of Alzheimer's disease in Australia. Neurology (1990) 40:1698–1707.
   PubMed Web of Science ®Google Scholar
• GRAVES AB, WHITE E, KOEPSELL TD et al.: A case-control study of Alzheimer's disease. Ann. Neurol (1990) 28:766–774.
   PubMed Web of Science ®Google Scholar
• BRENNER DE, KUKULL WA, STERGACHIS A et al.: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am. J. Epidemiol (1994) 140:262–267.
   PubMed Web of Science ®Google Scholar
• •A case-control study indicating no association between HT and AD risk, where hormone therapy exposure was based on computerised pharmacy records.
   Google Scholar
• MORTEL KF, MEYER JS: Lack of postmenopausal estrogen replacement therapy and the risk of dementia. Neuropsychiatry Clin. NeuroscL (1995) 7:334–337.
   PubMedGoogle Scholar
• SESHADRI S, ZOMBERG GL, DERBY LE, MYERS MW, JICK H, DRACHMAN DA: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch. Neurol (2001) 58:435–440.
   PubMed Web of Science ®Google Scholar
• BIRGE SJ: The role of estrogen deficiency in the aging central nervous system. In:Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Lobo RA (Ed.), Raven Press, New York, USA (1994):153–157.
   Google Scholar
• HENDERSON VW, PAGANINI-HILL A, EMANUEL CK, DUNN ME, BUCK WALTER JG: Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch. Neurol (1994) 51:896–900.
   PubMed Web of Science ®Google Scholar
• PAGANINI-HILL A, HENDERSON VW: Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. (1996) 156:2213–2217.
   PubMed Web of Science ®Google Scholar
• •A nested case-control study in the Leisure World retirement community, where hormone therapy was associated with a reduced risk of AD.
   Google Scholar
• TANG M-X, JACOBS D, STERN Y et al: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429–432.
   PubMedGoogle Scholar
• •A cohort study indicating that HT is associated with a reduced risk and delayed onset of AD.
   Google Scholar
• LERNER A, KOSS E, DEBANNE S, ROWLAND D, SMYTH K, FRIEDLAND R: Smoking and oestrogen replacement therapy as protective factors for Alzheimer's disease. Lancet (1997) 349:403-404 (Letter).
   Google Scholar
• KAWAS C, RESNICK S, MORRISON A et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology(1997) 48:1517–1521.
   PubMed Web of Science ®Google Scholar
• •A cohort study indicating that hormone therapy is associated with reduced AD risk.
   Google Scholar
• BALDERESCHI M, DI CARLO A, LEPORE V et al: Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology (1998) 50:996–1002.
   PubMed Web of Science ®Google Scholar
• WARING SC, ROCCA WA, PETERSEN RC, O'BRIEN PC, TANGALOS EG, KOKMEN E: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology (1999) 52:965–970.
   PubMed Web of Science ®Google Scholar
• SLOOTER AJ, BRONZOVA J, WITTEMAN JC, VAN BROECKHOVEN C, HOFMAN A, VAN DUIJN CM: Estrogen use and early onset Alzheimer's disease: a population-based study. J. Nemo] Neurosurg. Psychiatry (1999) 67:779–781.
   PubMedGoogle Scholar
• ZANDI PP, CARLSON MC,PLASSMAN BL et al.: Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study. JAMA (2002) 288:2123–2129.
   Google Scholar
• ••A cohort study indicating that past use ofHT is associated with reduced AD risk but current HT is unassociated with risk if used for 10 years.
   Google Scholar
• YAFFE K, SAWAYA G, LIEBERBURG I, GRADY D: Estrogen therapy in postmenopausal women. JAMA (1998) 279:688–695.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of HT and AD risk.
   Google Scholar
• HOGERVORST E, WILLIAMS J, BUDGE M, RIEDEL W, JOLLES J: The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience (2000) 101:485–512.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of HT and AD risk.
   Google Scholar
• LEBLANC ES, JANOWSKY J, CHAN BKS, NELSON HD: Hormone replacement therapy and cognition: systemic review and meta-analysis. JAMA (2001) 285:1489–1499.
   PubMed Web of Science ®Google Scholar
• •A meta-analysis of HT and AD risk.
   Google Scholar
• JOKELA H, DASTIDAR P, RONTU R et al.: Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J. Gin. Endocrinol Metal,. (2003) 88:4348–4354.
   PubMedGoogle Scholar
• RICE MM, GRAVES AB, MCCURRY SM et al.: Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame Project. Arch. Intern. Med. (2000) 160:1641–1649.
   PubMed Web of Science ®Google Scholar
• JEZIERSKI MK, SOHRABJI F: Neurotrophin expression in the reproductively senescent forebrain is refractory to estrogen stimulation. Neurobiol Aging (2001) 22:309–319.
   PubMed Web of Science ®Google Scholar
• SAVONENKO AV, MARKOWSKA AL: The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience (2003) 119:821–830.
   PubMed Web of Science ®Google Scholar
• •A study conducted in middle-aged and old rats indicating that some brain effects of oestrogen treatment after ovariectomy differ by age group.
   Google Scholar
• PHILLIPS SM, SHERWIN BB: Effects of estrogen on memory function in surgicallymenopausal women.Psychoneuroendocrinology (1992) 17:485–495.
   PubMed Web of Science ®Google Scholar
• BINDER EF, SCHECHTMAN KB, BIRGE SJ, WILLIAMS DB, KOHRT WM: Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas (2001) 38:137–146.
   PubMed Web of Science ®Google Scholar
• WOOLLEY CS, GOULD E, FRANKFURT M, MCEWEN BS: Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. Neurosci. (1990) 10:4035–4039.
   Google Scholar
• SILVA I, MELLO LEAM, FREYMOLLER E, HAIDAR MA, BARACAT EC: Onset of estrogen replacement has a critical effect on synaptic density of CA1 hippocampus in ovariectomized adult rats.Menopause (2003) 10:406–411.
   PubMedGoogle Scholar
• GIBBS RB: Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats.Neurobiol Aging(2000) 21:107–116.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, DUDLEY EC, GUTHRIE JR, BURGER HG, DENNERSTEIN L: Estrogen exposures and memory at midlife: a population-based study of women. Neurology (2003) 60:1369–1371.
   PubMed Web of Science ®Google Scholar
• MEYER PM, POWELL LH, WILSON RS et al.: A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology (2003) 61:801–806.
   PubMed Web of Science ®Google Scholar
• BRETT KM, CHONG Y: Hormone Replacement Therapy: Knowledge and Use M the United States. National Center for Health Statistics, Hyattsville, MD, USA (2001).
   Google Scholar
• ELIAS ME BEISER A, WOLF PA, AU R, WHITE RE D'AGOSTINO RB: The preclinical phase of Alzheimer's disease: a 22-year prospective study of theFramingham cohort. Arch. Neurol (2000) 57:808–813.
   PubMedGoogle Scholar
• SMALL BJ, FRATIGLIONI L, VIITANEN M, WINBLAD B, BACKMAN L: The course of cognitive impairment in preclinical Alzheimer's disease. Arch. Neurol (2000) 57:839–844.
   PubMed Web of Science ®Google Scholar
• RESNICK SM, HENDERSON VW: Hormone therapy and risk of Alzheimer's disease: a critical time. JAMA (2002) 288:2170–2172.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, PRESSMAN A, SILVER P: Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause (1999) 6:282–289.
   PubMed Web of Science ®Google Scholar
• COSGRAVE MP, TYRRELL J,MCCARRON M, GILL M, LAWLOR BA: Age at onset of dementia and age of menopause in women with Down's syndrome. J. Intellect. Disabil Res. (1999) 43:461–465.
   PubMed Web of Science ®Google Scholar
• SCHUPF N, PANG D, PATEL BN et al: Onset of dementia is associated with age at menopause in women with Down's syndrome. Ann. Nemo]. (2003) 54:433–438.
   PubMed Web of Science ®Google Scholar
• HEMMINKI E, MALIN M, TOPO P: Selection to postmenopausal therapy by women's characteristics. I. Clin. Epidemiol (1993) 46:211–219.
   PubMed Web of Science ®Google Scholar
• DERBY CA, HUME AL,MCPHILLIPS JB, BARBOUR MM, CARLETON RA: Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers. Am. J. Obstet. Cynecol (1995) 173:544–550.
   PubMed Web of Science ®Google Scholar
• MOORHEAD T, HANNAFORD P, WARSKYJ M: Prevalence and characteristics associated with use of hormone replacement therapy in Britain. Br. J. Obstet. Cynaecol. (1997) 104:290–297.
   PubMedGoogle Scholar
• WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal resultsfrom the Women's Health Initiative randomized controlled trial. JAMA (2002) 288:321–333.
   PubMedGoogle Scholar
• RAPP SR, ESPELAND MA, SHUMAKER SA et al.: The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Women's Health Initiative Memory Study. JAMA (2003) 289:2663–2672.
   PubMed Web of Science ®Google Scholar
• •The WHI randomised, controlled trial of continuous combined oestrogen plus progestin in women aged 65–79 years, indicating that oral oestrogen plus progestin does not enhance global cognition.
   Google Scholar
• BROWN TJ, SCHERZ B,HOCHBERG RB, MACLUSKY NJ: Regulation of estrogen receptor concentrations in the rat brain: effects of sustained androgen and estrogen exposure. Neuroendocrinology (1996) 63:53–60.
   PubMed Web of Science ®Google Scholar
• SHIMA N, YAMAGUCHI Y, YURI K: Distribution of estrogen receptor beta mRNA-containing cells in ovariectomized and estrogen-treated female rat brain. Anat. Sci. Int. (2003) 78:85–97.
   PubMedGoogle Scholar
• PETERSEN RC, DOODY R, KURZ A et al.: Current concepts in mild cognitive impairment. Arch. Nemo]. (2001) 58:1985–1992.
   PubMed Web of Science ®Google Scholar
• NILSEN J, BRINTON RD: Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. USA (2003) 100:10506–10511.
   PubMed Web of Science ®Google Scholar